TDMS Study 05200-06 Pathology Tables
NTP Experiment-Test: 05200-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NITROMETHANE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:10:52
Facility: Battelle Northwest
Chemical CAS #: 75-52-5
Lock Date: 06/22/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05200-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NITROMETHANE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:10:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 188 PPM 375 PPM 750 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 7 5 3 2
Moribund Sacrifice 16 17 20 12
Accidently Killed 2 1
Survivors
Terminal Sacrifice 25 27 26 36
Moribund Sacrifice 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (40) (45) (45) (46)
Intestine Large, Colon (49) (48) (47) (50)
Leiomyoma 1 (2%)
Intestine Large, Cecum (49) (46) (47) (50)
Intestine Small, Duodenum (48) (43) (45) (49)
Intestine Small, Jejunum (47) (45) (47) (48)
Intestine Small, Ileum (47) (46) (46) (49)
Liver (50) (49) (49) (50)
Hemangiosarcoma 2 (4%) 2 (4%)
Hepatocellular Carcinoma 7 (14%) 14 (29%) 8 (16%) 11 (22%)
Hepatocellular Carcinoma, Multiple 3 (6%) 1 (2%)
Hepatocellular Adenoma 11 (22%) 12 (24%) 13 (27%) 22 (44%)
Hepatocellular Adenoma, Multiple 3 (6%) 13 (27%) 4 (8%) 13 (26%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Mesentery (7) (14) (8) (11)
Hemangioma 1 (7%) 1 (9%)
Hemangiosarcoma 1 (13%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (7%)
Sarcoma 1 (7%)
Sarcoma, Metastatic, Skin 1 (14%)
Oral Mucosa (1) (1)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
Pancreas (50) (48) (48) (50)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (49) (48) (49) (50)
Hemangiosarcoma 1 (2%)
Stomach, Forestomach (50) (48) (49) (50)
Squamous Cell Papilloma 1 (2%) 1 (2%) 2 (4%)
Stomach, Glandular (49) (48) (48) (50)
Adenoma 1 (2%)
Page 2
NTP Experiment-Test: 05200-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NITROMETHANE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:10:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 188 PPM 375 PPM 750 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Pericardium, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (48) (49) (50)
Capsule, Adenoma 1 (2%) 1 (2%) 1 (2%)
Adrenal Medulla (50) (48) (49) (49)
Pheochromocytoma Benign 1 (2%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (48) (47) (50)
Adenoma 1 (2%)
Parathyroid Gland (33) (34) (33) (34)
Carcinoma 1 (3%)
Pituitary Gland (50) (46) (48) (50)
Pars Distalis, Adenoma 9 (18%) 10 (22%) 8 (17%) 4 (8%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (48) (48) (50)
Follicular Cell, Adenoma 4 (8%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (47) (47) (48) (48)
Cystadenocarcinoma 1 (2%)
Cystadenoma 2 (4%) 1 (2%) 3 (6%)
Granulosa Cell Tumor Benign 2 (4%)
Histiocytic Sarcoma 1 (2%)
Luteoma 1 (2%)
Teratoma Benign 1 (2%)
Uterus (50) (49) (49) (50)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Deciduoma Benign 1 (2%)
Page 3
NTP Experiment-Test: 05200-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NITROMETHANE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:10:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 188 PPM 375 PPM 750 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Hemangioma 2 (4%) 5 (10%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Polyp Stromal 4 (8%) 2 (4%) 1 (2%) 3 (6%)
Vagina (1)
Histiocytic Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (48) (49) (50)
Hemangiosarcoma 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Lymph Node (8) (6) (5) (6)
Lymph Node, Bronchial (39) (36) (40) (40)
Hepatocellular Carcinoma, Metastatic, Liver 2 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Lymph Node, Mandibular (43) (34) (38) (43)
Histiocytic Sarcoma 1 (2%) 1 (3%)
Lymph Node, Mesenteric (48) (46) (46) (48)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node, Mediastinal (38) (37) (35) (41)
Carcinoma, Metastatic, Harderian Gland 1 (3%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 1 (3%)
Spleen (50) (48) (49) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 2 (4%)
Mast Cell Tumor Malignant 1 (2%)
Thymus (43) (39) (41) (47)
Hepatocellular Carcinoma, Metastatic, Liver 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (48) (49) (50)
Adenoma 1 (2%)
Carcinoma 2 (4%) 2 (4%) 2 (4%)
Skin (49) (47) (50) (50)
Squamous Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 2 (4%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Page 4
NTP Experiment-Test: 05200-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NITROMETHANE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:10:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 188 PPM 375 PPM 750 PPM
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 2 (4%)
Osteosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (49) (48) (49) (50)
Lung (50) (50) (49) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 2 (4%) 2 (4%) 8 (16%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 3 (6%) 5 (10%)
Alveolar/Bronchiolar Carcinoma, Multiple 3 (6%)
Carcinoma, Metastatic, Harderian Gland 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 5 (10%) 3 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Hemangioma 1 (2%)
Mediastinum, Hemangiosarcoma 1 (2%)
Mediastinum, Hepatocellular Carcinoma,
Metastatic, Liver 2 (4%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%)
Mediastinum, Mast Cell Tumor Malignant 1 (2%)
Nose (50) (49) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (49) (49) (50) (50)
Adenoma 4 (8%) 6 (12%) 15 (30%) 16 (32%)
Adenoma, Multiple 1 (2%) 1 (2%) 1 (2%) 3 (6%)
Carcinoma 1 (2%) 2 (4%) 4 (8%) 2 (4%)
Carcinoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 05200-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NITROMETHANE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:10:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 188 PPM 375 PPM 750 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (48) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Urinary Bladder (49) (47) (47) (49)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 3 (6%)
Lymphoma Malignant 9 (18%) 7 (14%) 7 (14%) 7 (14%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05200-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NITROMETHANE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:10:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 188 PPM 375 PPM 750 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 38 45 43 46
Total Primary Neoplasms 83 95 92 110
Total Animals with Benign Neoplasms 31 39 33 43
Total Benign Neoplasms 48 62 50 82
Total Animals with Malignant Neoplasms 26 24 28 21
Total Malignant Neoplasms 35 33 42 28
Total Animals with Metastatic Neoplasms 4 5 3 4
Total Metastatic Neoplasm 11 14 5 5
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05200-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NITROMETHANE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:10:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 188 PPM 375 PPM 750 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 14 11 16 16
Natural Death 5 3 4 5
Survivors
Terminal Sacrifice 31 36 30 29
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Jejunum (45) (49) (47) (46)
Intestine Small, Ileum (46) (48) (46) (45)
Liver (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 2 (4%) 2 (4%)
Hepatocellular Carcinoma 11 (22%) 12 (24%) 8 (16%) 6 (12%)
Hepatocellular Carcinoma, Multiple 5 (10%) 2 (4%) 2 (4%) 3 (6%)
Hepatocellular Adenoma 10 (20%) 10 (20%) 12 (24%) 11 (22%)
Hepatocellular Adenoma, Multiple 7 (14%) 4 (8%) 1 (2%) 6 (12%)
Hepatocholangiocarcinoma, Multiple 1 (2%)
Histiocytic Sarcoma 3 (6%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Mesentery (3) (6) (2)
Fat, Histiocytic Sarcoma 2 (33%)
Pancreas (49) (50) (49) (49)
Adenoma 1 (2%)
Histiocytic Sarcoma 2 (4%)
Salivary Glands (50) (49) (50) (49)
Stomach, Forestomach (49) (50) (50) (48)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (48) (48) (48) (48)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05200-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NITROMETHANE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:10:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 188 PPM 375 PPM 750 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (50) (49) (48)
Adenoma 2 (4%)
Bilateral, Capsule, Adenoma 1 (2%)
Capsule, Adenoma 5 (10%) 1 (2%) 1 (2%) 3 (6%)
Adrenal Medulla (49) (50) (49) (47)
Pheochromocytoma Complex 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (49) (50) (49) (49)
Adenoma 1 (2%) 3 (6%) 1 (2%)
Pituitary Gland (47) (50) (46) (47)
Pars Distalis, Adenoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (50) (49) (48)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (49)
Histiocytic Sarcoma 2 (4%)
Prostate (49) (50) (47) (46)
Histiocytic Sarcoma 1 (2%)
Seminal Vesicle (49) (49) (49) (47)
Histiocytic Sarcoma 1 (2%)
Testes (50) (50) (50) (50)
Interstitial Cell, Adenoma 2 (4%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (50) (50)
Hemangiosarcoma 1 (2%) 2 (4%)
Lymph Node (3) (1) (1) (2)
Lymph Node, Bronchial (26) (26) (24) (28)
Histiocytic Sarcoma 1 (4%)
Lymph Node, Mandibular (40) (39) (37) (43)
Lymph Node, Mesenteric (47) (46) (47) (49)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Lymph Node, Mediastinal (35) (37) (36) (40)
Histiocytic Sarcoma 1 (3%)
Page 9
NTP Experiment-Test: 05200-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NITROMETHANE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:10:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 188 PPM 375 PPM 750 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Spleen (49) (50) (50) (49)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Thymus (33) (34) (33) (40)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (49) (49) (49) (48)
Prepuce, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 2 (4%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (49)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 9 (18%) 10 (20%) 8 (16%) 11 (22%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 3 (6%) 3 (6%) 10 (20%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 6 (12%) 1 (2%) 4 (8%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Mediastinum, Histiocytic Sarcoma 1 (2%)
Nose (50) (49) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (49) (50) (50) (49)
Adenoma 9 (18%) 6 (12%) 18 (36%) 25 (51%)
Adenoma, Multiple 4 (8%) 1 (2%) 7 (14%)
Carcinoma 1 (2%) 1 (2%) 6 (12%) 4 (8%)
Carcinoma, Multiple 1 (2%)
Page 10
NTP Experiment-Test: 05200-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NITROMETHANE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:10:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 188 PPM 375 PPM 750 PPM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM - cont
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (49)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (48) (50) (49) (48)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 3 (6%) 3 (6%) 1 (2%)
Lymphoma Malignant 3 (6%) 4 (8%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05200-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NITROMETHANE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:10:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 188 PPM 375 PPM 750 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 39 43 46
Total Primary Neoplasms 76 70 75 98
Total Animals with Benign Neoplasms 31 31 33 43
Total Benign Neoplasms 47 41 46 71
Total Animals with Malignant Neoplasms 22 25 24 22
Total Malignant Neoplasms 29 29 29 27
Total Animals with Metastatic Neoplasms 6 2 5 4
Total Metastatic Neoplasm 7 2 7 5
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------